Mesenteric Ischemia | NYU Langone Health
NYU Langone vascular specialists manage mesenteric ischemia, a rare and serious condition that limits blood flow to the intestines.
Mesoscopic Biomarkers of Neurodegeneration and Inflammation with Diffusion MRI
In this study, novel diffusion MRI markers in brain white matter will be evaluated to yield clinically feasible non-invasive MR markers that are sensitive and specific to diffuse neurodegenerative and inflammatory processes in brain white matter of Multiple Sclerosis patients. The white matter microstructure markers will be evaluated in their ability to track disease progression, both in a cross-sectional and longitudinal design in MS patients with a varying range of disability. Ultimately, the MRI pipeline for estimating WM microstructure markers will be straightforwardly extendable beyond MS, to help understand and quantify neurodegeneration and inflammation in other neurological diseases.
Metabolomics of World Trade Center-Lung Injury: Biomarker Validation Assessment and Dietary Intervention: Food Intake REstriction for Health OUtcome Support and Education (FIREHOUSE) Trial
This is a dietary intervention study that will examine the therapuetic effect of a Calorie Restricted Mediterranean (LoCalMed) diet on clinical endpoints such as FEV1, FeNO, vascular stiffness, and show concurrent changes of targeted biomarkers and quality of life measures. We will compare BMI changes, lung function, targeted biomarkers, quality of life measures, FeNO, and pulse wave velocity (PWV) pre- to post-intervention.
Metastatic Brain Tumors | NYU Langone Health
Perlmutter Cancer Center doctors treat people who have metastatic brain tumors, cancers that have spread to the brain from another part of the body.
METRO Lupus Consortium
The purpose of this study is to learn more about patients with lupus ("systemic lupus erythematosus" or "SLE") who may have injury to their kidney which is called lupus nephritis (LN). The goal of this study is to increase the number of new diagnostics and therapies for patients, and to reduce the time and cost of developing these new treatment options.
mHealth-CArdiac REhabilitation for INOCA (INOCA-CARE)
This study will enroll participants with the condition condition called Ischemia with No-Obstructive Coronary Arteries (INOCA), which means the participant has "open arteries" (no major heart artery is blocked at least halfway). The purpose of this study is to find out if an exercise program done at home, called mobile health cardiac rehabilitation or mHealth-CR, can improve the health and quality of life of patients with INOCA. The purpose of this study is to find out if an exercise program done at home, called mobile health cardiac rehabilitation or mHealth-CR, can improve the health and quality of life of patients with INOCA. In order to understand if it does, we need to divide the participants into 2 groups, mHealth-CR group and usual care group, and compare the results. Both groups will receive the usual medical care determined by their doctor and will receive a Fitbit to track their activity. The main difference between the 2 groups is that only one group (the mHealth-CR group) will get access to the mHealth-CR app (Corrie health) on their mobile phone and will work with an exercise therapist who will create a personalized exercise plan to be followed for 3 months. Interested potential eligible participants will join a screening visit (remote) in which, if they agree to participate in the study, they will sign an informed consent form. After consent, the study participation will involve 2 in-person visits (at baseline and 3 months) and 2 virtual visits (at 6 and 12 months). For more information about the INOCA-CARE research study please send us a message here or email us at inoca@nyulangone.org.
Microbial and host biomarkers for endotyping critically ill patients
We will prospectively collect airway, stool and blood samples on 1000 subjects admitted to the ICU with diagnosis of sepsis, acute respiratory distress symdrome (ARDS) or pneumonia. We will evaluate airway/gut microbial signatures associated with local (lower airway) and systemic (blood) immune tone. We will then study whether airway/gut microbial signatures are associated with clinical outcomes (Aim 1) and dysbiotic signatures are associated with host immune endotypes (Aim 2).
Microbial and Host Biomarkers for Endotyping Venous Thromboembolism Patients
This research aims to understand the differences between blood clotting caused by viruses affecting the whole body versus those affecting the lungs, and how different treatments affect our genes and molecules. We also want to study why some people are more likely to develop dangerous blood clots after getting treatment for vein blood clots. This study hopes to find out how treatments can be improved for people with vein blood clots. We'll enroll patients diagnosed with vein blood clots like those in the lungs or legs, who need treatment procedures. We'll also include patients diagnosed with vein blood clots who don't need a procedure, for comparison. All patients who agree will give blood samples and other samples during the study. Those having procedures will give samples during their treatment, and some may also give samples later for follow-up research.
Microbial and human biomarkers of thoracic disease after lung transplantation
We will prospectively collect airway and blood samples on 200 subjects undergoing lung transplantation. We will evaluate airway microbial signatures associated with local (lower airway) and systemic (blood) immune tone. We will then study whether host or transplant related factors affect microbiota and/or host signatures (Aim 1) and whether these signatures predict subjects’ longitudinal development of lung dysfunction and chronic lung allograft dysfunction (CLAD, Aim 2).
MICROBiome Involvement in Outcomes of Methotrexate Efficacy-RA
This is a prospective, observational, proof-of-principle, open-label, single-blinded study looking at the effects of the gut microbiome on the metabolism and response to methotrexate treatment and related medications. MTX will be taken at standard-of-care doses in drug-naïve RA patients who have active disease and have not received other disease-modifying therapies (as defined by the inclusion/exclusion criteria).